Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 1 , Pages 64-66 , January 2009

Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA)

  • Stacy Loeb, M.D.

      Affiliations

    • James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    • ,
  • Sara N. Gashti, B.S.

      Affiliations

    • Department of Urology, Northwestern Feinberg School of Medicine, Chicago, IL 60611, USA
    • ,
  • William J. Catalona, M.D.

      Affiliations

    • Department of Urology, Northwestern Feinberg School of Medicine, Chicago, IL 60611, USA
    • Corresponding Author InformationCorresponding author. Tel.: 312-695-4471; fax: 312-695-1482

References 

  1. Loeb S, Roehl KA, Antenor JA, et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006;67(2):316–320
  2. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267(16):2215–2220
  3. Loeb S, Roehl KA, Nadler RB, et al. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. J Urol. 2007;178(6):2348–2352Discussion 2352–3
  4. Moul JW, Sun L, Hotaling JM, et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol. 2007;177(2):499–503Discussion 503–4
  5. Link RE, Shariat SF, Nguyen CV, et al. Variation in prostate specific antigen results from two different assay platforms: Clinical impact on 2,304 patients undergoing prostate cancer screening. J Urol. 2004;171(6 Pt 1):2234–2238
  6. Roehrborn CG, Pickens GJ, Carmody T. Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Urology. 1996;47(1):59–66
  7. Ornstein DK, Smith DS, Rao GS, et al. Biological variation of total, free, and percent free serum prostate specific antigen levels in screening volunteers. J Urol. 1997;157(6):2179–2182
  8. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: An evaluation of year-to-year fluctuations. JAMA. 2003;289(20):2695–2700
  9. Dalton DL. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology. 1989;33(6):465
  10. Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2 Pt 1):407–413
  11. Kandirali E, Boran C, Serin E, et al. Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology. 2007;70(4):743–747
  12. Eggener SE, Yossepowitch O, Roehl KA, et al. The relationship of PSA velocity to histologic findings in a prostate cancer screening program. Urology. 2008;in press
  13. Schaeffer AJ, Wu SC, Tennenberg AM, et al. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol. 2005;174(1):161–164
  14. Serretta V, Catanese A, Daricello G, et al. PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. Prostate Cancer Prostatic Dis [Epub ahead of print 17 July 2007].
  15. Cannon G, Smaldone MC, Paterson DL. Extended-spectrum β-lactamase gram-negative sepsis following prostate biopsy: Implications for use of fluoroquinolone prophylaxis. Can J Urol. 2007;14(4):3653–3655

PII: S1078-1439(08)00076-8

doi: 10.1016/j.urolonc.2008.04.002

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 1 , Pages 64-66 , January 2009

Article Tools